Burzynski Research Institute (BZYR) Retained Earnings (2011 - 2025)
Burzynski Research Institute (BZYR) posted Retained Earnings of -$130.5 million for Q4 2025, little changed sequentially from -$130.1 million in Q3 2025, and down 1.0% YoY from -$131.8 million in Q4 2024.
Burzynski Research Institute (BZYR) Retained Earnings (2011 - 2025) Analysis & Trends
Burzynski Research Institute has reported Retained Earnings for 15 years, with the latest figure at -$130.5 million in Q4 2025.
- Quarterly Retained Earnings fell 1.0% year-over-year to -$130.5 million in Q4 2025, while the trailing twelve-month figure through Nov 2025 was -$130.5 million (down 1.0% YoY) and the FY2025 annual result came in at -$129.5 million, down 1.08% from the prior year.
- Retained Earnings was little changed at -$130.5 million in Q4 2025 per BZYR's latest filing, from -$130.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$124.9 million in Q1 2021 and troughed at -$130.5 million in Q4 2025.
- A 5-year average of -$127.5 million and a median of -$127.2 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings slipped 0.69% in 2022, then retreated 1.21% in 2024.
- Over 5 years, Retained Earnings stood at -$125.7 million in 2021, then fell by 0.69% to -$126.5 million in 2022, then decreased by 0.94% to -$127.7 million in 2023, then dropped by 1.14% to -$129.2 million in 2024, then fell by 1.0% to -$130.5 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$130.5 million, -$130.1 million, and -$129.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -130.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -130.47 Mn |
| Aug 31, 2025 | -130.14 Mn |
| May 31, 2025 | -129.81 Mn |
| Feb 28, 2025 | -129.48 Mn |
| Nov 30, 2024 | -129.18 Mn |
| Aug 31, 2024 | -128.83 Mn |
| May 31, 2024 | -128.46 Mn |
| Feb 29, 2024 | -128.09 Mn |
| Nov 30, 2023 | -127.73 Mn |
| Aug 31, 2023 | -127.29 Mn |
| May 31, 2023 | -127.04 Mn |
| Feb 28, 2023 | -126.75 Mn |
| Nov 30, 2022 | -126.54 Mn |
| Aug 31, 2022 | -126.29 Mn |
| May 31, 2022 | -126.07 Mn |
| Feb 28, 2022 | -125.84 Mn |
| Nov 30, 2021 | -125.67 Mn |
| Aug 31, 2021 | -125.40 Mn |
| May 31, 2021 | -125.18 Mn |
| Feb 28, 2021 | -124.86 Mn |